Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms

Xu Wenbin; Yan Han; Xu Lulu; Li Mingna; Gao Wentao; Jiang Kuirong; Wu Junli; Miao Yi

doi:10.7555/JBR.34.20200039

Volume 35 Issue 3

May 2021

Turn off MathJax

Article Contents

Abstract

References

The Journal of Biomedical Research > 2021 > 35(3): 179-188. > DOI: 10.7555/JBR.34.20200039

Xu Wenbin, Yan Han, Xu Lulu, Li Mingna, Gao Wentao, Jiang Kuirong, Wu Junli, Miao Yi. Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms[J]. The Journal of Biomedical Research, 2021, 35(3): 179-188. DOI: 10.7555/JBR.34.20200039

Citation:

PDF (2040 KB)

Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms

Xu Wenbin^{1, 2},
Yan Han^{1, 2},
Xu Lulu³,
Li Mingna⁴,
Gao Wentao^{1, 2},
Jiang Kuirong^{1, 2},
Wu Junli^{1, 2},
Miao Yi^{1, 2, ,}

1.
Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
2.
Pancreas Institute of Nanjing Medical University, Nanjing, Jiangsu 210029, China
3.
Department of Radiology
4.
Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

More Information

Corresponding author:
Yi Miao, Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Tel: +86-25-6830-6590, E-mail: miaoyi@njmu.edu.cn
Received Date: March 17, 2020
Revised Date: June 13, 2020
Accepted Date: June 18, 2020
Available Online: August 20, 2020

Graphical Abstract

Abstract

Abstract

Contrast-enhanced computed tomography (CT) contributes to the increasing detection of pancreatic neuroendocrine neoplasms (PNENs). Nevertheless, its value for differentiating pathological tumor grades is not well recognized. In this report, we have conducted a retrospective study on the relationship between the 2017 World Health Organization (WHO) classification and CT imaging features in 94 patients. Most of the investigated features eventually provided statistically significant indicators for discerning PNENs G3 from PNENs G1/G2, including tumor size, shape, margin, heterogeneity, intratumoral blood vessels, vascular invasion, enhancement pattern in both contrast phases, enhancement degree in both phases, tumor-to-pancreas contrast ratio in both phases, common bile duct dilatation, lymph node metastases, and liver metastases. Ill-defined tumor margin was an independent predictor for PNENs G3 with the highest area under the curve (AUC) of 0.906 in the multivariable logistic regression and receiver operating characteristic curve analysis. The portal enhancement ratio (PER) was shown the highest AUC of 0.855 in terms of quantitative features. Our data suggest that the traditional contrast-enhanced CT still plays a vital role in differentiation of tumor grades and heterogeneity analysis prior to treatment.
- pancreatic neuroendocrine neoplasm,
- computed tomography,
- tumor grade,
- heterogeneity analysis

FullText(HTML)

References (30)

References

[1]	Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063–3072. doi: 10.1200/JCO.2007.15.4377
[2]	Reid MD, Balci S, Saka B, et al. Neuroendocrine tumors of the pancreas: current concepts and controversies[J]. Endocr Pathol, 2014, 25(1): 65–79. doi: 10.1007/s12022-013-9295-2
[3]	Ricci C, Casadei R, Taffurelli G, et al. WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old?[J]. Pancreatology, 2014, 14(6): 539–541. doi: 10.1016/j.pan.2014.09.005
[4]	Inzani F, Petrone G, Rindi G. The new world health organization classification for pancreatic Neuroendocrine Neoplasia[J]. Endocrinol Metab Clin North Am, 2018, 47(3): 463–470. doi: 10.1016/j.ecl.2018.04.008
[5]	Kim JH, Eun HW, Kim YJ, et al. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma[J]. Eur Radiol, 2016, 26(5): 1338–1347. doi: 10.1007/s00330-015-3941-7
[6]	Guo CG, Zhuge XL, Wang ZQ, et al. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade[J]. Abdom Radiol, 2019, 44(2): 576–585. doi: 10.1007/s00261-018-1763-1
[7]	Kang J, Ryu JK, Son JH, et al. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm[J]. J Gastroenterol Hepatol, 2018, 33(9): 1677–1682. doi: 10.1111/jgh.14139
[8]	Kulali F, Semiz-Oysu A, Demir M, et al. Role of diffusion-weighted MR imaging in predicting the grade of nonfunctional pancreatic neuroendocrine tumors[J]. Diagn Interv Imaging, 2018, 99(5): 301–309. doi: 10.1016/j.diii.2017.10.012
[9]	Okabe H, Hashimoto D, Chikamoto A, et al. Shape and enhancement characteristics of pancreatic neuroendocrine tumor on preoperative contrast-enhanced computed tomography may be prognostic indicators[J]. Ann Surg Oncol, 2017, 24(5): 1399–1405. doi: 10.1245/s10434-016-5630-4
[10]	Toshima F, Inoue D, Komori T, et al. Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?[J]. Jpn J Radiol, 2017, 35(5): 242–253. doi: 10.1007/s11604-017-0627-x
[11]	Belousova E, Karmazanovsky G, Kriger A, et al. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades[J]. Clin Radiol, 2017, 72(2): 150–158. doi: 10.1016/j.crad.2016.10.021
[12]	Kim DW, Kim HJ, Kim KW, et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour[J]. Eur Radiol, 2015, 25(5): 1375–1383. doi: 10.1007/s00330-014-3532-z
[13]	Takumi K, Fukukura Y, Higashi M, et al. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade[J]. Eur J Radiol, 2015, 84(8): 1436–1443. doi: 10.1016/j.ejrad.2015.05.005
[14]	Luo YJ, Dong Z, Chen J, et al. Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification[J]. Eur Radiol, 2014, 24(11): 2945–2952. doi: 10.1007/s00330-014-3317-4
[15]	Cappelli C, Boggi U, Mazzeo S, et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours[J]. Eur Radiol, 2015, 25(3): 751–759. doi: 10.1007/s00330-014-3485-2
[16]	Canellas R, Burk KS, Parakh A, et al. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis[J]. AJR Am J Roentgenol, 2018, 210(2): 341–346. doi: 10.2214/AJR.17.18417
[17]	D'Onofrio M, Ciaravino V, Cardobi N, et al. CT enhancement and 3D texture analysis of pancreatic neuroendocrine neoplasms[J]. Sci Rep, 2019, 9(1): 2176. doi: 10.1038/s41598-018-38459-6
[18]	Horiguchi S, Kato H, Shiraha H, et al. Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm[J]. J Gastroenterol Hepatol, 2017, 32(4): 925–931. doi: 10.1111/jgh.13594
[19]	Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch[J]. Nat Rev Cancer, 2003, 3(6): 401–410. doi: 10.1038/nrc1093
[20]	Ellis LM, Takahashi Y, Fenoglio CJ, et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma[J]. Eur J Cancer, 1998, 34(3): 337–340. doi: 10.1016/S0959-8049(97)10068-5
[21]	Duarte IG, Bufkin BL, Pennington MF, et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg, 1998, 115(3): 652–659. doi: 10.1016/S0022-5223(98)70331-9
[22]	Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Natl Cancer Inst, 1992, 84(24): 1875–1887. doi: 10.1093/jnci/84.24.1875
[23]	Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas[J]. Ann Oncol, 1995, 6(1): 59–64. doi: 10.1093/oxfordjournals.annonc.a059043
[24]	Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors[J]. Clin Cancer Res, 2007, 13(1): 187–196. doi: 10.1158/1078-0432.CCR-06-1408
[25]	Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors[J]. Gastroenterology, 2003, 125(4): 1094–1104. doi: 10.1016/S0016-5085(03)01198-3
[26]	d'Assignies G, Couvelard A, Bahrami S, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors[J]. Radiology, 2009, 250(2): 407–416. doi: 10.1148/radiol.2501080291
[27]	Yamada S, Fujii T, Suzuki K, et al. Preoperative identification of a prognostic factor for pancreatic neuroendocrine tumors using multiphase contrast-enhanced computed tomography[J]. Pancreas, 2016, 45(2): 198–203. doi: 10.1097/MPA.0000000000000443
[28]	Choi TW, Kim JH, Yu MH, et al. Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis[J]. Acta Radiol, 2018, 59(4): 383–392. doi: 10.1177/0284185117725367
[29]	Basturk O, Yang ZH, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms[J]. Am J Surg Pathol, 2015, 39(5): 683–690. doi: 10.1097/PAS.0000000000000408
[30]	Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases[J]. Histopathology, 2018, 72(1): 168–177. doi: 10.1111/his.13408

[1]	Hamed Amini Amirkolaee, Hamid Amini Amirkolaee. Medical image translation using an edge-guided generative adversarial network with global-to-local feature fusion[J]. The Journal of Biomedical Research, 2022, 36(6): 409-422. DOI: 10.7555/JBR.36.20220037
[2]	Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
[3]	Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
[4]	Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
[5]	Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
[6]	Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
[7]	Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
[8]	Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
[9]	Xiaoquan Xu, Feiyun Wu, Yunxiang Chen, Hao Hu, Meiling Bao. CT and multimodal imaging findings of primary orbital Ewing's sarcoma involving the middle cranial fossa: a case report[J]. The Journal of Biomedical Research, 2017, 31(2): 170-174. DOI: 10.7555/JBR.30.20140132
[10]	Samia M. Elsherief, Mohamed K. Zayet, Ibrahim M. Hamouda. Cone-beam computed tomography analysis of curved root canals after mechanical preparation with three nickel-titanium rotary instruments[J]. The Journal of Biomedical Research, 2013, 27(4): 326-335. DOI: 10.7555/JBR.27.20130008

Cited By

Cited by

Periodical cited type(2)

1.	Kartik A, Armstrong VL, Stucky CC, et al. Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors. Cancers (Basel), 2024, 16(8): 1501. DOI:10.3390/cancers16081501
2.	Zhang J, Zhu H, Shen L, et al. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib. Chin J Cancer Res, 2023, 35(5): 526-535. DOI:10.21147/j.issn.1000-9604.2023.05.09

Other cited types(0)

Get Citation

PDF

XML

Article Metrics

Article views (1202) PDF downloads (121) Cited by(2)

CiteScore

Impact Factor

Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms